SG11201601844TA - Anti-pd1 antibodies and their use as therapeutics and diagnostics - Google Patents

Anti-pd1 antibodies and their use as therapeutics and diagnostics

Info

Publication number
SG11201601844TA
SG11201601844TA SG11201601844TA SG11201601844TA SG11201601844TA SG 11201601844T A SG11201601844T A SG 11201601844TA SG 11201601844T A SG11201601844T A SG 11201601844TA SG 11201601844T A SG11201601844T A SG 11201601844TA SG 11201601844T A SG11201601844T A SG 11201601844TA
Authority
SG
Singapore
Prior art keywords
therapeutics
diagnostics
anti
use
pd1 antibodies
Prior art date
Application number
SG11201601844TA
Inventor
Jing Song
Kang Li
Tong Zhang
Lanlan Xu
Qi Liu
Hao Peng
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Priority to PCT/CN2013/083467 priority Critical patent/WO2015035606A1/en
Publication of SG11201601844TA publication Critical patent/SG11201601844TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11201601844TA 2013-09-13 2013-09-13 Anti-pd1 antibodies and their use as therapeutics and diagnostics SG11201601844TA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/083467 WO2015035606A1 (en) 2013-09-13 2013-09-13 Anti-pd1 antibodies and their use as therapeutics and diagnostics

Publications (1)

Publication Number Publication Date
SG11201601844TA true SG11201601844TA (en) 2016-04-28

Family

ID=50736425

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201601844TA SG11201601844TA (en) 2013-09-13 2013-09-13 Anti-pd1 antibodies and their use as therapeutics and diagnostics

Country Status (16)

Country Link
US (5) US8735553B1 (en)
EP (1) EP3044234A4 (en)
JP (1) JP2016533763A (en)
KR (1) KR20160044063A (en)
CN (4) CN105531288A (en)
AU (1) AU2013400609A1 (en)
BR (1) BR112016005408A2 (en)
CA (1) CA2924172A1 (en)
EA (1) EA201690567A1 (en)
HK (1) HK1217501A1 (en)
IL (1) IL244514D0 (en)
MX (1) MX2016003292A (en)
SG (1) SG11201601844TA (en)
TW (1) TWI636995B (en)
WO (1) WO2015035606A1 (en)
ZA (1) ZA201601953B (en)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2634098T3 (en) 2011-01-14 2017-09-26 The Regents Of The University Of California therapeutic antibodies ROR-1 protein and procedures for use thereof.
RS57508B1 (en) 2013-09-06 2018-10-31 Aurigene Discovery Tech Limited 1,2,4-oxadiazole derivatives as immunomodulators
EP3041468B1 (en) 2013-09-06 2018-06-13 Aurigene Discovery Technologies Limited Cyclic peptidomimetic compounds as immunomodulators
WO2015033301A1 (en) 2013-09-06 2015-03-12 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
CA2924172A1 (en) 2013-09-13 2015-03-19 Beigene, Ltd. Anti-pd1 antibodies and their use as therapeutics and diagnostics
RU2676158C1 (en) 2013-12-20 2018-12-26 Интервет Интернэшнл Б.В. Caninised murine antibodies to human pd-1
PE02552017A1 (en) 2014-01-24 2017-03-22 Dana-Farber Cancer Inst Inc Antibody molecules that bind to PD-1 and uses thereof
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
MX2016011832A (en) 2014-03-12 2017-05-12 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns.
TW201625684A (en) 2014-06-26 2016-07-16 Macrogenics Inc Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof
EP3171892A4 (en) * 2014-07-22 2018-01-17 CB Therapeutics, Inc. Anti-pd-1 antibodies
US9982053B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
TW201618775A (en) 2014-08-11 2016-06-01 艾森塔製藥公司 Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, a PD-1 inhibitor and/or a PD-L1 inhibitor
WO2016033555A1 (en) 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
KR20170065032A (en) 2014-10-14 2017-06-12 할로자임, 아이엔씨 Compositions of Adenosine Deaminase-2 (ADA2), Variants thereof and Methods of Using Same
EP3218409A2 (en) * 2014-11-11 2017-09-20 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
US9605080B2 (en) 2014-11-21 2017-03-28 Bristol-Myers Squibb Company Antibodies against CD73
TW201625693A (en) 2014-11-21 2016-07-16 Squibb Bristol Myers Co Antibodies against CD73 and uses thereof
CN106146667A (en) * 2015-03-27 2016-11-23 四川大学华西医院 Exendin-4 fusion protein, preparation method and uses thereof
CN108136001A (en) 2015-04-03 2018-06-08 佐马技术有限公司 Treatment of cancer using inhibitors of tgf-beta and pd-1
US10174113B2 (en) 2015-04-28 2019-01-08 Bristol-Myers Squibb Company Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody
US20160362489A1 (en) 2015-04-28 2016-12-15 Bristol-Myers Squibb Company Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
WO2016179472A2 (en) * 2015-05-07 2016-11-10 University Of Maryland, Baltimore Modulation of natural killer cell tolerance
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US20180162942A1 (en) 2015-05-29 2018-06-14 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
AU2016271591A1 (en) 2015-05-29 2017-12-21 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
CN105061597B (en) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 An anti-pd-1 monoclonal antibodies and a method of obtaining
WO2017011580A2 (en) * 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
CN107922502A (en) 2015-07-14 2018-04-17 百时美施贵宝公司 Method of treating cancer using immune checkpoint inhibitor
US20190127467A1 (en) * 2015-07-30 2019-05-02 Macrogenics, Inc. PD-1-Binding Molecules and Methods of Use Thereof
WO2017025498A1 (en) 2015-08-07 2017-02-16 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for lag-3 and pd-1
CN107949573A (en) * 2015-09-01 2018-04-20 艾吉纳斯公司 Anti-PD-1 antibodies and methods of use thereof
KR20180083318A (en) * 2015-09-29 2018-07-20 아시아 바이오테크 피티이. 엘티디. Pd-1 antibodies and their use
EP3356551A1 (en) 2015-09-29 2018-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the metabolic status of lymphomas
US10183060B2 (en) * 2015-10-01 2019-01-22 Heat Biologics, Inc. Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
CN106632674B (en) * 2015-10-30 2018-11-16 泽达生物医药有限公司 An anti-pd-1 monoclonal antibodies, pharmaceutical compositions and uses thereof
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
US20180371092A1 (en) 2015-11-18 2018-12-27 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
EP3394093A1 (en) 2015-12-23 2018-10-31 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
WO2017118634A1 (en) 2016-01-04 2017-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
WO2017122175A1 (en) 2016-01-13 2017-07-20 Acerta Pharma B.V. Therapeutic combinations of an antifolate and a btk inhibitor
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
MX2018010021A (en) 2016-02-17 2018-11-09 Novartis Ag Tgfbeta 2 antibodies.
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
US20190127439A1 (en) * 2016-05-17 2019-05-02 Albert Einstein College Of Medicine, Inc. Engineered pd-1 variants
CN109195621A (en) 2016-05-18 2019-01-11 莫得纳特斯公司 The polynucleotides and application thereof of encoding Interleukin 12 (IL12)
AU2017268399A1 (en) 2016-05-18 2019-01-17 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
KR20190020299A (en) 2016-05-18 2019-02-28 모더나티엑스, 인크. Combinations and their use in the mRNA that encodes the immunomodulating polypeptide
CN106008714B (en) * 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 Anti-human PD-1 Humanized monoclonal antibodies and its application
EP3464360A1 (en) 2016-05-27 2019-04-10 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
KR20190015377A (en) 2016-06-02 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 pd-1 blocks with nibol rumap in Hodgkin lymphoma refractory No.
AU2017274444A1 (en) 2016-06-02 2018-12-13 Bristol-Myers Squibb Company Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in lymphoma treatment
CN109476753A (en) 2016-06-03 2019-03-15 百时美施贵宝公司 For treating the anti-PD-1 antibody of the method for tumour
CN109476754A (en) 2016-06-03 2019-03-15 百时美施贵宝公司 Purposes of the anti-PD-1 antibody in treatment colorectal cancer patients
WO2017214182A1 (en) * 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
WO2017218533A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
AU2017281830A1 (en) 2016-06-20 2018-12-13 Kymab Limited Anti-PD-L1 antibodies
WO2018007885A1 (en) * 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
WO2018059437A1 (en) * 2016-09-27 2018-04-05 Beigene, Ltd. Treatment cancers using combination comprising parp inhibitors
AU2017343621A1 (en) 2016-10-11 2019-04-11 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018081621A1 (en) 2016-10-28 2018-05-03 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
AU2017355446A1 (en) 2016-11-03 2019-05-02 Bristol-Myers Squibb Company Activatable anti-CTLA-4 antibodies and uses thereof
TW201819408A (en) * 2016-11-18 2018-06-01 Symphogen As Anti-PD-1 antibodies and compositions
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
WO2018132739A2 (en) 2017-01-13 2018-07-19 Agenus Inc. T cell receptors that bind to ny-eso-1 and methods of use thereof
WO2018134279A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
TW201833135A (en) 2017-01-20 2018-09-16 法商賽諾菲公司 Anti -TGF-β antibodies and uses thereof
WO2018134784A1 (en) 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
WO2018146612A1 (en) 2017-02-10 2018-08-16 Novartis Ag 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
TW201835077A (en) 2017-02-17 2018-10-01 美商英能腫瘤免疫股份有限公司 Nlrp3 modulator
UY37621A (en) 2017-02-28 2018-09-28 Sanofi Sa therapeutic RNA encoding cytokines
WO2018172508A1 (en) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CN107082812B (en) * 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 The fusion protein for recovering debilitating immune cell function and its application
WO2018183928A1 (en) 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor
WO2018231339A2 (en) * 2017-04-20 2018-12-20 Dana-Farber Cancer Institute, Inc. Anti-phosphotyrosinylated pd-1 antibodies and uses thereof
WO2018204303A1 (en) * 2017-05-01 2018-11-08 The Children's Medical Center Coporation Methods and compositions relating to anti-pd1 antibody reagents
TW201900166A (en) 2017-05-19 2019-01-01 瑞士商諾華公司 By the administration of a tumor to the treatment of solid tumors compounds and compositions
WO2018222722A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
WO2018222711A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
WO2018220546A1 (en) 2017-05-31 2018-12-06 Novartis Ag Crystalline forms of 5-bromo-2,6-di(1 h-pyrazol-1-yl)pyrimidin-4-amine and new salts
US20190010246A1 (en) 2017-06-01 2019-01-10 Compugen Ltd. Triple combination antibody therapies
WO2018223040A1 (en) 2017-06-01 2018-12-06 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-pd-1 antibody
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
TW201904993A (en) 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β binding antibody purposes
TW201906866A (en) * 2017-06-26 2019-02-16 英屬開曼群島商百濟神州有限公司 Acid sphingomyelinase deficiency in patients with abnormal bone condition treatment
EP3421494A1 (en) 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
WO2019014402A1 (en) 2017-07-14 2019-01-17 Innate Tumor Immunity, Inc. Nlrp3 modulators
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019023459A1 (en) 2017-07-28 2019-01-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019023624A1 (en) 2017-07-28 2019-01-31 Bristol-Myers Squibb Company Predictive peripheral blood biomarker for checkpoint inhibitors
WO2019046321A1 (en) 2017-08-28 2019-03-07 Bristol-Myers Squibb Company Tim-3 antagonists for the treatment and diagnosis of cancers
WO2019046498A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046496A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046500A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046856A1 (en) 2017-09-04 2019-03-07 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019075468A1 (en) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company Methods of treating tumor
WO2019079261A1 (en) 2017-10-16 2019-04-25 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019090330A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Methods of treating a tumor

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
JPH07291996A (en) 1994-03-01 1995-11-07 Yuu Honshiyo Polypeptide related to programmed cell death in human, dna coding the same, vector consisting of the same dna, host cell transformed with the same vector, antibody of the same polypeptide and pharmaceutical composition containing the same polypeptide or the same antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (en) 1999-01-15 2011-10-31 Genentech Inc. Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant
PT1210428E (en) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, a receptor for b7-4, and uses therefor
MXPA02001878A (en) 1999-08-23 2003-08-20 Dana Farber Cancer Inst Inc Novel b74 molecules and uses therefor.
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
KR20030066657A (en) 2000-11-15 2003-08-09 오노 야꾸힝 고교 가부시키가이샤 Pd-1-lacking mouse and use thereof
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR20090010127A (en) 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 Expression technology for proteins containing a hybrid isotype antibody moiety
AR036993A1 (en) 2001-04-02 2004-10-20 Wyeth Corp Use of agents that modulate the interaction between PD-1 and its ligands in undershoot of immune responses
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
DK1537878T3 (en) 2002-07-03 2011-01-24 Ono Pharmaceutical Co Immunopotentiating compositions
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
WO2004056875A1 (en) * 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
EP1664116A4 (en) 2003-08-22 2009-06-03 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
MX2007013978A (en) 2005-05-09 2008-02-22 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics.
US8652465B2 (en) * 2005-06-08 2014-02-18 Emory University Methods and compositions for the treatment of persistent infections
CN104356236A (en) 2005-07-01 2015-02-18 梅达雷克斯有限责任公司 Human Monoclonal Antibodies To Programmed Death Ligand 1 (PD-L1)
ZA200804679B (en) 2005-12-08 2010-02-24 Millenium Pharmaceuticals Inc Bicyclic compounds with kinase inhibitory activity
CA2630344C (en) * 2006-03-23 2015-04-28 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
EP2021327B1 (en) 2006-05-15 2012-04-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CN101104640A (en) 2006-07-10 2008-01-16 苏州大学 Preparation for anti human PD-L1 monoclonal antibody and application thereof
AU2008255352B2 (en) * 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
BRPI0812913B1 (en) * 2007-06-18 2018-08-07 Merck Sharp & Dohme B.V. Monoclonal antibodies or antibody fragment to human PD programmed death receptor-1 polynucleotide, method for producing said antibodies or antibody fragments, comprising the composition and use thereof
WO2009024531A1 (en) 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP2012500855A (en) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッドAmplimmune, Inc. Pd-1 antagonists and methods for treating infectious diseases
EP2342229A1 (en) 2008-09-12 2011-07-13 ISIS Innovation Limited Pd-1 specific antibodies and uses thereof
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
DK2342226T3 (en) * 2008-09-26 2016-09-26 Dana-Farber Cancer Inst Inc Human anti-PD-1, PD-L1 and PD-L2 antibodies and uses thereof
KR101050829B1 (en) 2008-10-02 2011-07-20 서울대학교산학협력단 Wherein pd-1 antibody or an anti-cancer drug comprising a pd-l1 antibody
SG172059A1 (en) * 2008-12-09 2011-07-28 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
US20100197924A1 (en) 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
WO2010089411A2 (en) * 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
CN102971340A (en) 2010-03-29 2013-03-13 酵活有限公司 Antibodies with enhanced or suppressed effector function
EA201390923A1 (en) * 2010-12-22 2013-12-30 Сефалон Острэйлиа Пти Лтд. The modified antibody with improved half-life
CN103476795B (en) * 2011-03-29 2016-07-06 罗切格利卡特公司 Antibody Fc variants
ES2676205T3 (en) * 2011-03-31 2018-07-17 Merck Sharp & Dohme Stable formulations of antibodies to human PD-1 receptor programmed death and related treatments
CN103608040B (en) * 2011-04-20 2017-03-01 米迪缪尼有限公司 B7-h1 binding antibodies and other molecules of pd-1
JP6141834B2 (en) * 2011-06-06 2017-06-07 ノヴォ ノルディスク アー/エス Therapeutic antibody
KR20140063643A (en) * 2011-08-01 2014-05-27 제넨테크, 인크. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
EP2813568A4 (en) 2012-02-09 2016-04-06 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
AU2013256802A1 (en) 2012-04-30 2014-12-11 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
CA2873402A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN104994873B (en) 2012-10-04 2017-12-22 达纳-法伯癌症研究所公司 Human monoclonal antibody and anti--pd-l1 use
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme Antibodies that bind to human ligand 1 programmed death (pd-l1)
TWI635098B (en) 2013-02-01 2018-09-11 再生元醫藥公司 Antibodies containing the chimeric constant region
SG11201505383UA (en) * 2013-02-20 2015-08-28 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
AU2014240101B2 (en) * 2013-03-15 2018-05-17 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
CA2924172A1 (en) 2013-09-13 2015-03-19 Beigene, Ltd. Anti-pd1 antibodies and their use as therapeutics and diagnostics
JP2017522905A (en) 2014-07-03 2017-08-17 ベイジーン リミテッド Use for anti-pd-l1 antibodies and their therapeutic and diagnostic
US9139653B1 (en) * 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies

Also Published As

Publication number Publication date
AU2013400609A8 (en) 2016-07-21
US20150315274A1 (en) 2015-11-05
US20180111995A1 (en) 2018-04-26
HK1217501A1 (en) 2017-01-13
US9217034B2 (en) 2015-12-22
BR112016005408A2 (en) 2018-01-16
KR20160044063A (en) 2016-04-22
CA2924172A1 (en) 2015-03-19
MX2016003292A (en) 2016-06-24
TWI636995B (en) 2018-10-01
CN107011441A (en) 2017-08-04
IL244514D0 (en) 2016-04-21
US20180251551A1 (en) 2018-09-06
EA201690567A1 (en) 2016-08-31
US20150079109A1 (en) 2015-03-19
JP2016533763A (en) 2016-11-04
CN105531288A (en) 2016-04-27
EP3044234A4 (en) 2017-08-09
TW201538525A (en) 2015-10-16
US8735553B1 (en) 2014-05-27
CN108715615A (en) 2018-10-30
US9834606B2 (en) 2017-12-05
AU2013400609A1 (en) 2016-05-05
ZA201601953B (en) 2017-06-28
EP3044234A1 (en) 2016-07-20
CN107090041B (en) 2018-11-16
US9988450B2 (en) 2018-06-05
CN107090041A (en) 2017-08-25
WO2015035606A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
EP2956175A4 (en) Chimeric antigen receptor and methods of use thereof
SG11201505072RA (en) Antibodies comprising chimeric constant domains
IL246287D0 (en) Fabs-in-tandem immunoglobulin and uses thereof
HK1222679A1 (en) Cd19 specific chimeric antigen receptor and uses thereof cd19
SG10201800250XA (en) Anti-cd3 antibodies and methods of use
GB201413149D0 (en) No details
EP2970505A4 (en) Bispecific antibodies and uses thereof
EP3044234A4 (en) Anti-pd1 antibodies and their use as therapeutics and diagnostics
ZA201601294B (en) Anti-activin a antibodies and uses thereof
EP3160505A4 (en) Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
HK1220161A1 (en) Diagnostic systems and methods
SG11201505745WA (en) Anti-il-33 antibodies and uses thereof
EP2971130A4 (en) Sequential sequencing
HK1217958A1 (en) Tetravalent bispecific antibodies
TWI559292B (en) Anc system with spl-controlled output
TWI595007B (en) Anti-mcam antibodies and associated methods of use
EP2970307A4 (en) Pyrazolo compounds and uses thereof
GB201305668D0 (en) Avs6 Integrin Antagonists
SG11201510739TA (en) Humanized or chimeric cd3 antibodies
EP2951642A4 (en) Omnistereo imaging
GB2508037B (en) Chair
TWI609882B (en) Bispecific antibodies and methods of using the same
EP2968304A4 (en) 4-phenylpiperidines, their preparation and use
SG11201602414SA (en) Chimeric antigen receptor
ZA201505705B (en) Phi-4 polypeptides and methods for their use